Avenue Therapeutics, Inc. has been informed by the Division of Corporation Finance Office of Life Sciences that the United States Securities and Exchange Commission (SEC) will not review the company's Registration Statement on Form S-3, which was filed on May 6, 2024. The SEC's communication, dated May 8, 2024, was addressed to Dr. Alexandra MacLean, CEO of Avenue Therapeutics. The SEC also reminded the company of its responsibility for the accuracy and adequacy of disclosures, irrespective of the SEC's review process. The SEC provided contact information for any further questions and referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process.

Avenue Therapeutics, Inc. has been informed by the Division of Corporation Finance Office of Life Sciences that the United States Securities and Exchange Commission (SEC) will not review the company's Registration Statement on Form S-3, which was filed on May 6, 2024. The SEC's communication, dated May 8, 2024, was addressed to Dr. Alexandra MacLean, CEO of Avenue Therapeutics. The SEC also reminded the company of its responsibility for the accuracy and adequacy of disclosures, irrespective of the SEC's review process. The SEC provided contact information for any further questions and referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process.